Idiopathic Pulmonary Fibrosis - Treatment

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link:

Contents of this Issue


Page 3 of 3

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at Copyright © 2015 All rights reserved ATSIPF15073a Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations IPF, idiopathic pulmonary fibrosis; q12h, every 12 hours; tid, 3 times a day Source An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192: e3–e19. Available at: e guidelines were a cooperative effort among the American oracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American oracic Society. Table 3. Quality of the Evidence (GRADE) and Implications Quality of Evidence Symbol Implications High ⊕⊕⊕⊕ Further research is very unlikely to change confidence in the estimate of effect. Moderate ⊕⊕⊕⊖ Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate. Low ⊕⊕⊖⊖ Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Very low ⊕⊖⊖⊖ e guideline committee is very uncertain about the estimate. e quality of the evidence is a judgment about the extent to which we can be confident that the estimates of effect are correct. ese judgments are made for each outcome using the GRADE system. e judgments are based upon the study design (randomized trials, observational studies, or other), risk of bias, consistency of results across studies, and precision of the overall estimates across studies. For each outcome, the quality of the evidence is rated as high, moderate, low, or very low. (For more information about the GRADE system, see: )

Articles in this issue

Links on this page

view archives of ATS GUIDELINES Bundle - Idiopathic Pulmonary Fibrosis - Treatment